Brought to you by 
Daiichi to buy majority of Indian generics giant Ranbaxy
10 Apr 2014
Executive Summary
Daiichi Sankyo is diversifying into the generic drugs industry by acquiring a majority ownership in public Indian company Ranbaxy Laboratories, one of the top ten generics players worldwide. The transaction is valued between $3.4-4.6bn.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi to buy majority of Indian generics giant Ranbaxy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice